Soligenix, Inc
Biopharmaceutical therapeutics for rare diseases
- Sector
- Biotech
- Headquarters
- Princeton, NJ
- Latest Form D
- $2M, Nov 2017
- Total capital
- $64.7M
- Federal grants
- $7.5M
- 9 awards · 2017–2021
- Rank in peer group#350 of 514
- Private capital raised
- $18.1M
- 7 Form D · last Nov 2017
- 108 months since last filing
- Federal contracts
- $39.1M
- 3 awards · Health and Human S
- Rank in Biotech#22 of 4373
- Granted patents
- 8
- 17 pending · first 2017
- Rank in peer group#40 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP$830K
- Federal grantHealth and Human S · Phase II · Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP$1.5M
- Federal grantHealth and Human S · Phase II · Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP$637K
- Federal grantHealth and Human S · Phase I · "Dusquetide for the treatment of oral mucositis in the pediatric population"$150K
- Federal grantHealth and Human S · Phase II · Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma$750K
- Federal grantHealth and Human S · Phase II · SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer$750K
- Private capital raisedForm D · SEC · 7th filing$2M
- Private capital raisedForm D · SEC · 6th filing$1.5M
- Private capital raisedForm D · SEC · 5th filing$5.9M
- Private capital raisedForm D · SEC · 4th filing$300K
- Private capital raisedForm D · SEC · 3rd filing$4.5M
- Private capital raisedForm D · SEC · 2nd filing$2.4M
- Private capital raisedForm D · SEC · 1st filing$1.5M
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma$750K
- Federal grantHealth and Human S · Phase II · SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer$1.5M
- Federal grantHealth and Human S · Phase II · SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer$715K
- Federal contractHealth and Human S · Igf::ot::igf Development Of Vaccine Formulations Effective Against Niaid Priority Pathogens$21.2M
- Federal contractHealth and Human S · Igf::ct,cl::igf Development Of Medical Countermeasures To Mitigate Or Treat The Gastrointestinal Acute Radiation Syndrome After A Nuclear Or Radiation Incident$7M
- Federal contractHealth and Human S · Igf::ot::igf Orbeshield Development Program$10.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#40 · top 8%
- Linked publications#36 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Adam T. RumageExecutive OfficerNamed in SEC Form D filings
- Brian L. Hamilton, M.D., Ph.D.Executive OfficerNamed in SEC Form D filings
- Christopher J. Schaber, PhDExecutive Officer, DirectorNamed in SEC Form D filings
- Christopher J. Schaber, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Christopher P. Schnittker, C.P.A.Executive OfficerNamed in SEC Form D filings
- Cyrille F. BuhrmanDirectorNamed in SEC Form D filings
Show all 24 people
- Evan J. MyrianthopoulosExecutive Officer, DirectorNamed in SEC Form D filings
- Gregg A. LaPointe, CPADirectorNamed in SEC Form D filings
- Gregg A. Lapointe, C.P.A.DirectorNamed in SEC Form D filings
- Gregg A. Lapointe, C.P.A., M.B.A.DirectorNamed in SEC Form D filings
- Jerome B. Zeldis, M.D., Ph.D.DirectorNamed in SEC Form D filings
- Jerome B. Zeldis, PhDDirectorNamed in SEC Form D filings
- Joseph M. Warusz, C.P.A.Executive OfficerNamed in SEC Form D filings
- Karen Christopher KrumeichExecutive OfficerNamed in SEC Form D filings
- Keith L. Brownlie, CPADirectorNamed in SEC Form D filings
- Keith L. Brownlie, C.P.A.DirectorNamed in SEC Form D filings
- Kevin J. Horgan, M.D.Executive OfficerNamed in SEC Form D filings
- Marco M. Brughera, DVMDirectorNamed in SEC Form D filings
- Oreola Christopher Donini, PhDExecutive OfficerNamed in SEC Form D filings
- R. Christopher Cavalli, PhDExecutive OfficerNamed in SEC Form D filings
- Richard C. Straube, MD MScExecutive OfficerNamed in SEC Form D filings
- Robert N. Brey, Ph.D.Executive OfficerNamed in SEC Form D filings
- Robert J. Rubin, MDDirectorNamed in SEC Form D filings
- Robert J. Rubin, M.D.DirectorNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 25- PendingCompositions and Methods of Treatment of Certain Vasculitis SyndromesUSPTOApplication 18963115
- GrantedThermostable Vaccine Compositions and Methods of Preparing sameUSPTOUS 12,097,291
- PendingDermatological Compositions and Methods of Treatment against Cutaneous T-Cell LymphomaUSPTOApplication 17860599
Show all 25 patent records
- Compositions and Methods of Treatment of Certain Vasculitis SyndromesJun 19, 2025 · Application 18963115Pending
- Thermostable Vaccine Compositions and Methods of Preparing sameSep 24, 2024 · US 12,097,291Granted
- Dermatological Compositions and Methods of Treatment against Cutaneous T-Cell LymphomaJan 26, 2023 · Application 17860599Pending
- Novel Peptides and Analogs for Use in the Treatment of Oral MucositisApr 26, 2022 · US 11,311,598Granted
- Topically Active Steroids for Use in Radiation and Chemotherapeutics InjuryMay 21, 2020 · Application 16448526Pending
- Systems And Methods For Producing Synthetic HypericinJan 7, 2020 · US 10,526,268Granted
- Multivalent Stable Vaccine Composition And Methods Of Making SameMay 21, 2019 · US 10,293,041Granted
- Novel Peptides And Analogs For Use In The Treatment Of Oral MucositisApr 9, 2019 · US 10,253,068Granted
- Systems And Methods For Producing Synthetic HypericinAug 21, 2018 · US 10,053,413Granted
- Thermostable Vaccine Compositions and Methods of Preparing SameApr 5, 2018 · Application 15694023Pending
- Novel Peptides And Analogs For Use In The Treatment Of Oral MucositisDec 26, 2017 · US 9,850,279Granted
- Topically Active Steroids For Use in Radiation and Chemotherapeutics InjuryNov 23, 2017 · Application 15495798Pending
- Topically Active Steroids for Use In Interstitial Pulmonary FibrosisSep 19, 2017 · US 9,763,963Granted
- Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation SyndromeMay 28, 2015 · Application 14523341Pending
- Method of Preventing Acute Graft-Versus-Host Disease using Oral Beclomethasone DipropionateNov 6, 2014 · Application 14361103Pending
- Antibody/adjuvant Compositions And Methods Of Immune Response Generation Against CoronavirusesApplication PCTUS2023012795Pending
- Compositions And Methods Of Treatment Of Certain Vasculitis SyndromesApplication PCTUS2024057863Pending
- Multivalent Stable Vaccine Composition And Methods Of Making SameApplication PCTUS2015039826Pending
- Dermatological Compositions And Methods Of Treatment Against Cutaneous T-cell LympomaApplication PCTUS2022036551Pending
- Novel Peptides And Analogs For Use In The Treatment Of Macrophage Activation SyndromeApplication PCTUS2014062173Pending
- Novel Peptides And Analogs For Use In The Treatment Of Oral MucositisApplication PCTUS2014050516Pending
- Method Of Preventing Acute Graft-versus-host Disease Using Oral Beclomethasone DipropionateApplication PCTUS2012067462Pending
- Topically Active Steroids For Use In Radiation And Chemotherapeutics InjuryApplication PCTUS2009067199Pending
- Systems And Methods For Making Synthetic HypericinApplication PCTUS2016020189Pending
- Topically Active Steroids For Use In Interstitial Pulmonary FibrosisApplication PCTUS2009032015Pending
Recent research by its founders
- Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL20260 cites
- Therapeutic apheresis: A promising method to remove microplastics?202512 cites
- Neutrophil Extracellular Traps (NETs) as a Potential Target for Anti-Aging: Role of Therapeutic Apheresis20257 cites
Related companies, and why
- METABOLON, INC.Similar federal contract value in Biotech · $42M in contracts
- EITR BIOLOGICS, INC.Similar federal contract value in Biotech · $39.6M in contracts
- Sciome LLCSimilar federal contract value in Biotech · $39.3M in contracts
- PROFECTUS BIOSCIENCES, INC.Similar federal contract value in Biotech · $38.3M in contracts
- Argos TherapeuticsSimilar federal contract value in Biotech · $38.2M in contracts
- APTITUDE MEDICAL SYSTEMS INCSimilar federal contract value in Biotech · $36.5M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .